Specificity of seven monoclonal antibodies against p53 evaluated with western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry

Cytometry

Volumn 28, Issue 1, 1997, Pages 11-24

  Bonsing, Bert A ^a   Corver, Willem E ^a   Gorsira, Michael C B ^b   Van Vliet, Margreethe ^c   Oud, Peter S ^d   Cornelisse, Cees J ^a   Fleuren, Gert Jan ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Internal Medicine   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d Becton Dickinson Cell Imaging S   (Netherlands)

Author keywords

Breast carcinoma; Confocal laser scanning microscopy; Flow cytometry; Immunohistochemistry; Monoclonal antibodies; p53; Tumor heterogeneity; Western blotting

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; TUMOR CELL LINE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0030952502     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.0.CO;2-K     Document Type: Article

References (63)

1. Abrams ES, Murdaugh SE, Lerman LS: Comprehensive detection of single base changes in human genomic DNA using denaturing gradient gel electrophoresis and a GC clamp. Genomics 7:463-475, 1990.
2. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McCuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993.
3. Ball RK, Siegl B, Quellhorst S, Brandner G, Braun DG: Monoclonal antibodies against simian virus 40 nuclear large T tumor antigen: Epitope mapping, papova virus cross-reaction and cell surface staining. EMBO 3:1485-1491, 1984.
4. Banks L, Matlashewski G, Crawford L: Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159:529-534, 1986.
5. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P: p53 and c-erbB-2 protein expression in breast carcinomas. Am J Clin Pathol 98:408-418, 1992.
6. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma. Hum Pathol 24:469-476, 1993.
7. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703, 1991.
8. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP: Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 46:839-844, 1990.
9. Bartek J, Iggo R, Gannon JV, Lane DP: Genetic and immunolocalization analysis of mutant p53 in human breast cancer cell lines. Oncogene 5:893-899, 1990.
10. Beerman H, Smit VTHBM, Kluin PM, Bonsing BA, Hermans J, Cornelisse CJ: Flow-cytometric analysis of DNA stemline heterogeneity in primary and metastatic breast cancer. Cytometry 12:147-154, 1991.
11. Bonsing BA, Beerman H, Kuipers-Dijkshoorn NJ, Fleuren GJ, Cornelisse CJ: High Levels of DNA index heterogeneity in advanced breast carcinomas. Evidence for DNA ploidy differences between lymphatic and hematogenous metastases. Cancer 71:382-391, 1993.
12. Borresen A-L, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen T, Nesland JM, Isselbacher KJ, Friend SH: Constant denaturing gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 88:8405-8409, 1991.
13. Brotherick I. Lennard TWJ, Wilkinson SE, Cook S, Angus B, Shenton BK: Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay. Cytometry 16:262-269, 1994.
14. Brotherick I, Shenton BK, Cowan WK, Angus B, Horne CHW, Higgs MJ, Lennard TWJ: p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. Cancer Immunol Immunother 41:146-150, 1995.
15. Carder P, Wyllie AH, Purdie CA, Morris RG, White S, Piris J, Bird CC: Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8:1397-1401, 1993.
16. Casey, Lo-Huesh M, Lopez ME, Vogelstein B, Stanbridge EJ: Growth suppression of human breast cancer cells by the introduction of a wild type p53 gene. Oncogene 6:179-1797, 1991.
17. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D: p53 Expression in breast cancer. Int J Cancer 41:178-83, 1988.
18. Cornelis RS, van Vliet M, Vos CJB, Cleton-Jansen AM, van de Vijver MJ, Peterse JL, Meera Kahn P, Borresen A-L, Cornelisse CJ: Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res 54:4200-4206, 1994.
19. Corver WE, Bonsing BA, Abeln ECA, Vlak-Theil PM, Cornelisse CJ, Fleuren GJ: One tube triple staining method for flow cytometric analysis of DNA ploidy and phenotypic heterogeneity of human solid tumors using single laser excitation. Cytometry 25:358-366, 1996.
20. Corver WE, Cornelisse CJ, Fleuren GJ: Simultaneous measurement of two cellular antigens and DNA using fluorescein-isothiocyanate, R-phycoerythrin, and propidium iodide on a standard FACScan. Cytometry 15:117-128, 1994.
21. Corver WE, Cornelisse CJ, Hermans J, Fleuren GJ: Limited loss of nine tumor-associated surface antigenic determinants after tryptic cell dissociation. Cytometry 19:267-272, 1995.
22. Danova M, Giordano M, Mazzini G, Riccardi A: Expression of p53 protein during the cell cycle measured by flow cytometry in human leukemia. Leuk Res 14:417-422, 1990.
23. Davidoff AM, Kerns BM, Iglehard JD, Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51:2605-2610, 1991.
24. de Boer CJ, Schuuring E, Dreef E, Peters G, Bartek J, Kluin PM, van Krieken JHJM: Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 86:2715-2723, 1995.
25. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, Smith HS: Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res 54:499-505, 1994.
26. Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M: Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol 142:669-674, 1993.
27. Elledge R, Clark GM, Fuqua SAW, Yu YY, Allred DC: p53 protein accumulation detected by five different antibodies: Relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res. 54:3752-3757, 1994.
28. Ensley JF, Maciorowski Z, Pietraszkiewicz H, Hassan M, Kish J, Al-Sarraf M, Jacobs J, Weaver A, Atkinson D: Solid tumor preparation for clinical application of flow cytometry. Cytometry 8:488-493. 1987.
29. Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO 9:1595-1602, 1990.
30. Gruis NA, Abein ECA, Bardoel AFJ, Devilee P, Frants RR, Cornelisse CJ: PCR-based microstatellite polymorphisms in the detection of loss of heterozygosity in fresh and archival tumour tissue. Br J Cancer 68:308-313, 1993.
31. Hall PA, Lane DP: Editorial: p53 in tumour pathology: Can we trust immunohistochemistry? Revisited! J Pathol 172:1-4, 1994.
32. Harlow E, Crawford LV, Pim DC, Williamson NM: Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol 39:861-869, 1981.
33. Harlow E, Lane DP: Antibodies: A Laboratory Manual. 1st Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988, pp 1-726.
34. Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, Harris AL: Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6:2277-2284, 1991.
35. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991.
36. Kastan MB, Radin Al, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, Stone KD, Woo T, Ravindranath Y: Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 51:4279-4286, 1991.
37. Kuppen PJK, Schuitemaker H, Van't Veer LJ, De Bruijn EA, Van Oosterom AT, Schrier PI: cis-Diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48:3355-3359, 1988.
38. Lane DP: p53, guardian of the genome. Nature 358:15-16, 1992.
39. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991.
40. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, Callahan R, Bistocchi M: p53 mutations and histological type of invasive breast carcinoma. Cancer Res 53:4665-4669, 1993.
41. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S: Relationship between p53 expression and other prognostic factors in human breast carcinoma. Am J Clin Pathol 100:213-217, 1993.
42. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ: Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716-7719, 1987.
43. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S: Mutations in the p53 gene in diverse tumour types. Nature 342:705-708, 1989.
44. Petersen SE, Bichel P, Lorentzen M: Flow-cytometric demonstration of tumour-cell subpopulations with different DNA content in human colorectal carcinoma. Eur J Cancer Clin Oncol 15:383-386, 1978.
45. Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW, Ellis IO: p53 protein expression in human breast carcinoma: Relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. Br J Cancer 66:583-588, 1992.
46. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO: p53 expression in mammary ductal carcinoma in situ. Hum Pathol 24:463-468, 1993.
47. Porter PL, Gown AM, Kramp SG, Coltrera MD: Widespread p53 overexpression in human malignant tumors. Am J Pathol 140:145-153, 1992.
48. Raycroft L, Wu H, Lozano G: Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051, 1990.
49. Shaw P, Bavey R, Tardy S, Sahli R, Sordat B, Costa J: Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495-4499, 1992.
50. Sheikh MS, Shao ZM, Hussain A, Fontana JA: The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53:3226-3228, 1993.
51. Singh S, Simon M, Meybohm I, Jantke I, Jonat W, Maass H, Goedde HW: Human breast cancer: Frequent p53 allele loss and protein overexpression. Hum Genet 90:635-640, 1993.
52. Smit VTHBM, Wessels JW, Mollevanger P, Schrier PI, Raap AK, Beverstock GC, Cornelisse CJ: Combined GTC-banding and non-radioactive in situ hybridization improves characterization of complex karyotypes. Cytogenet Cell Genet 54:20-23, 1990.
53. Spicer SS, Spivey MA, Ito M, Schulte BA: Some ascites monoclonal antibody preparations contain contaminants that bind to selected Golgi zones or mast cells. J Histochem Cytochem 42:213-221, 1994.
54. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, Evans HJ, Steel CM: p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 50:528-532, 1992.
55. Thor AD, Moore, D II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz. L, Chen LC: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992.
56. Top B: A simple method to attach a universal 50-bp GC-clamp to PCR fragments used for mutation analysis by DGGE. PCR Meth Appl 2:83-85, 1992.
57. Trudel M, Mulligan L, Cavenee W, Margolese R, Cote J, Garpiery G: Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol 23:1388-1394, 1992.
58. Van Muijen GNP, Warnaar SO, Ponec M: Differentiation-related changes of cytokeratin expression in cultured keratinocytes and in fetal, newborn, and adult epidermis. Exp Cell Res 171:331-345, 1987.
59. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C, Walker RA: Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6:413-421, 1991.
60. Vindelov LL, Hansen HH, Christensen IJ, Spang-Thomsen M, Hirsch FR, Hansen M, Nissen NI: Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric analysis. Cancer Res 40:4295-4300, 1980.
61. Vojtesek B, Bartek J, Midgley CA, Lane DP: An immunohistochemical analysis of the human nuclear phosphoprotein p53; new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237-244, 1992.
62. Wade-Evans A, Jenkins JR: Precise epitope mapping of the murine transformation-associated protein p53. EMBO 4:699-706, 1985.
63. Walker RA, Dearing SJ, Lane DP, Varley JM: Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 165:203-211, 1991.